January 10, 2012

Pfizer Animal Health launches Suvaxyn PCV2 vaccine 

With the launch of Suvaxyn^® PCV2 by Pfizer Animal Health, swine producers in South East Asia now have a new option for effective protection against porcine circovirus type 2 (PCV2), with a single dose vaccine that carries a claim for the prevention of viraemia associated with field infections of immunosuppressive porcine circovirus.

Suvaxyn PCV2 is labelled for use as an aid in preventing viraemia and an aid in the control of PCV2-related lymphoid depletion for pigs three weeks of age and older. Suvaxyn PCV2 provides four months duration of immunity against PCV in a single 2-mL dose.

Dr. Yong Ming, DVM, Swine Marketing Manager (Bios) for Pfizer Animal Health Asia Pacific, said, "Suvaxyn PCV2 offers swine veterinarians and producers a new choice for long-lasting, consistent protection against PCV2. Additionally, with our new one day of age vaccination claim for RespiSure-ONE^®, we can provide an innovative programme for Mycoplasma and circovirus control. These registered vaccination regimes give veterinarians and their producers the flexibility to vaccinate for these key pathogens before the typical onset of disease challenge, providing the best immunity coverage possible."

PCV2 in the blood plays an important role in the development of PCVAD such as PMWS and PRDC as noted by key PCV2 experts. Suvaxyn PCV2 has been proven in a programme of experimental and field studies to significantly reduce viraemia and virus shedding and to improve body weight gain in PCV2 challenged pigs.

Suvaxyn PCV2 is backed by a sales and technical team dedicated to serving the swine industry, encompassing Pfizer training programmes to improve on-farm productivity and herd health. Suvaxyn PCV2 is now available in North America (under the trade name Fostera^® PCV), Mexico, Central America, Philippines, Thailand and Malaysia.